topical reviews
A perspective on structural and mechanistic aspects of protein O-fucosylation
aCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark, bBIFI, University of Zaragoza, BIFI–IQFR (CSIC) Joint Unit, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain, and cFundación ARAID, Avenida de Ranillas, 50018 Zaragoza, Spain
*Correspondence e-mail: erandi@sund.ku.dk, rhurtado@bifi.es
Protein O-fucosylation is an important post-translational modification (PTM) found in cysteine-rich repeats in proteins. Protein O-fucosyltransferases 1 and 2 (PoFUT1 and PoFUT2) are the enzymes responsible for this PTM and selectively glycosylate specific residues in epidermal growth factor-like (EGF) repeats and thrombospondin type I repeats (TSRs), respectively. Within the past six years, crystal structures of both enzymes have been reported, revealing important information on how they recognize protein substrates and achieve catalysis. Here, the structural information available today is summarized and how PoFUT1 and PoFUT2 employ different catalytic mechanisms is discussed.
Keywords: O-fucosylation; protein O-fucosyltransferases; epidermal growth factor-like repeats; EGF repeats; thrombospondin type I repeats; TSRs; enzyme mechanisms; GDP-fucose.
1. Introduction
Fucose is an important biological sugar that can be found as part of various glycoconjugates and is one of the two L-configuration (Bertozzi & Rabuka, 2009). Fucose modifications of proteins, mostly known as O-fucosylation, play multiple roles in cellular events. In mammals, there are 13 glycosyltransferases (GTs) that are capable of adding a fucose residue using GDP-fucose as the sugar donor, but only two GTs, protein O-fucosyltransferases 1 and 2 (PoFUT1 and PoFUT2), can directly glycosylate protein side chains (Schneider et al., 2017). Both PoFUT1 and PoFUT2 transfer fucose from GDP-fucose to serine or threonine residues in cysteine-rich repeats in proteins. However, while PoFUT1 glycosylates epidermal growth factor-like (EGF) repeats within the consensus sequence C2-X-X-X-X-S/T-C3 (Haltom & Jafar-Nejad, 2015), PoFUT2 glycosylates thrombospondin type I repeats (TSRs) containing Ser/Thr residues located in the consensus sequences C1-X-X-S/T-C2 or C2-X-X-S/T-C3 of TSRs of groups 1 and 2 (see below), respectively (Schneider et al., 2017).
present in mammals with anEGF repeats are small domains ranging between 30 and 40 amino acids, characterized by the formation of three disulfide bridges with the arrangement C1–C3, C2–C4 and C5–C6 (Savage et al., 1973). TSRs are larger than EGF repeats (∼60 amino acids) and can be split into two groups owing to their disulfide-bridge arrangement. The disulfide bridges of group 1 TSR are arranged as C1–C5, C2–C6 and C3–C4, while TSRs of group 2 adopt the pattern C1–C4, C2–C5 and C3–C6 (Leonhard-Melief & Haltiwanger, 2010). Although the disulfide-bridge arrangement differs between the two groups, the C2–C6 and C3–C6 disulfide bridges are conserved (Leonhard-Melief & Haltiwanger, 2010). PoFUT1 and PoFUT2 both require correctly folded repeats for O-fucosylation to take place (Luo, Nita-Lazar et al., 2006; Wang & Spellman, 1998) and both isoforms are highly selective for each repeat (Luo, Koles et al., 2006; Luo, Nita-Lazar et al., 2006), suggesting that the different disulfide-bridge arrangements and consensus sequences are essential features for substrate recognition. This review outlines recent progress in unveiling the differences in the reaction mechanisms and protein-substrate recognition of these enzymes, and the importance of O-fucosylation in protein–protein interaction.
2. PoFUT1 and PoFUT2 protein substrates
The first substrate of PoFUT1 to be identified was the urinary type 1 plasminogen activator (Kentzer et al., 1990). Now, approximately 100 proteins with EGF repeats are predicted to be O-fucosylated, although only a few have been confirmed (for a thorough review, see Schneider et al., 2017). The Notch receptors, which are transmembrane type I proteins that form part of the Notch signalling pathway, are the most studied PoFUT1 substrates. Most of the EGF repeats present in the four Notch receptors found in mammals enclose the consensus sequence required for O-fucosylation by PoFUT1 (Takeuchi & Haltiwanger, 2014). Notch ligands, two in Drosophila (Delta and Serrate) and three Delta-like and two Serrate-like ligands in mammals (Dll1, Dll3, Dll4, Jagged1 and Jagged2; D'Souza et al., 2008), also contain EGF repeats that can be O-fucosylated by PoFUT1 (Schneider et al., 2017).
Notch glycosylation is an elegant example of how the cell uses protein glycosylation to tune signalling-pathway activity. The elongation of Notch1 O-fucose by the addition of an N-acetylglucosamine (GlcNAc) moiety by Fringe GTs directs the specificity of the Notch receptors towards Delta and reduces Notch activation by Jagged proteins (Xu et al., 2007). Recent crystallographic complexes between Notch1 and its ligands (DLL4 and Jagged) show that the fucose moiety also plays an essential role in ligand interaction (Luca et al., 2015, 2017). The O-fucose moiety at Notch1 EGF12 Thr466 contributes significantly to recognizing DLL4 by hydrogen-bonding and hydrophobic interactions with the DLL4 MNNL domain (module at the N-terminus of the Notch ligand; Fig. 1a; Luca et al., 2015). However, the complex between Notch1 and Jagged1 is stabilized by interactions between Notch1 EGF12 Thr466-O-fucose and the Jagged1 C2 domain and also between Notch1 EGF8 Thr311-O-fucose and Jagged1 EGF3 (Fig. 1b). These interactions between Jagged1 and Notch1 provide an explanation of why Jagged1 binds sixfold more tightly to Notch1 EGFs 8–12 than a construct containing only EGFs 11–12 (Luca et al., 2017). Notch signalling plays a significant role in cell development, and its malfunction can lead to several diseases, including various types of cancer (Allenspach et al., 2002). The glycosylation of Notch receptors may also play a role in aberrant signalling (Takeuchi & Haltiwanger, 2014), and in this sense it has been reported that PoFUT1 is overexpressed in some cancer types (Kroes et al., 2007; Loo et al., 2013; Yokota et al., 2013).
Despite the prediction of more than 50 protein substrates, very little is known about the TSR O-fucose function (Schneider et al., 2017). The first O-fucosylated TSRs described in the literature were found on thrombospondin-1 (TSP1; Hofsteenge et al., 2001). Subsequently, PoFUT2 was isolated and characterized, following the realization that PoFUT1 does not glycosylate TSRs (Luo, Nita-Lazar et al., 2006; Luo, Koles et al., 2006). ADAMT and ADAMT-like proteins are a large family of proteins that are predicted to have several TSRs that are potentially O-fucosylated by PoFUT2 (Kelwick et al., 2015; Schneider et al., 2017), and O-fucose is a requirement for the efficient secretion of some of these proteins (Ricketts et al., 2007; Wang et al., 2007; Vasudevan et al., 2015; Benz et al., 2016). Very recently, it has been reported that depletion of PoFUT2 in Plasmodium falciparum results in attenuated infection of the mosquito vector and human hepatocytes. The authors concluded that this effect was owing to the loss of trafficking of PoFUT2 target proteins (Lopaticki et al., 2017).
3. The PoFUT1/2 GDP-fucose binding site is highly conserved
The first reported crystal structures of protein O-fucosyltransferases were those of Caenorhabditis elegans PoFUT1 (CePoFUT1) in the unliganded form (PDB entry 3zy4) and in complex with GDP and GDP-fucose (PDB entries 3zy3 and 3zy6) (Lira-Navarrete et al., 2011). The human PoFUT1 (HsPoFUT1) was reported in the free form and in the presence of GDP-fucose (PDB entries 5ux6 and 5uxh; Li et al., 2017), and crystal structures of Mus musculus PoFUT1 (MmPoFUT1) in complex with different EGF repeats (PDB entries 5kxh, 5ky0, 5ky2, 5ky3, 5ky4, 5ky5, 5ky7, 5ky8 and 5ky9) have also been reported (Li et al., 2017). Regarding PoFUT2, there are two crystal structures available for human PoFUT2: in the free form and complexed with GDP-fucose (PDB entries 4ap5 and 4ap6; Chen et al., 2012). In addition, the ternary complex between CePoFUT2, GDP and the human TSR1 (HsTSR1) repeat (PDB entry 5foe) has been described. Note that the latter complex is the only structure of PoFUT2 known to include an acceptor-protein substrate (Valero-González et al., 2016).
Both PoFUT1 and PoFUT2 present the typical GT-B fold, which consists of two Rossmann-like domains facing each other with the active site lying within the resulting deep cleft formed between them (Fig. 2a; Lairson et al., 2008). Although both enzymes share the same type of folding, the superimposition of apo forms of human PoFUT1 and PoFUT2 renders a poor root-mean-square deviation (r.m.s.d.) on 174 equivalent Cα atoms of 3.03 Å (Fig. 2b), which is in agreement with the observed low sequence identity (∼28% identity). This difference between the HsPoFUT1 and HsPoFUT2 crystal structures is mainly attributed to the presence of two prominent loops in HsPoFUT2 that are absent in HsPoFUT1. While loop260–287 is located in the C-terminal domain with no apparent function in catalysis, loop141–155 contributes to the formation of the cleft in which the acceptor substrate is located (Fig. 2b). HsPoFUT1 also has additional secondary elements that are formed by residues Ser243–Leu284, which encompass three α-helices and a 310-helix (Fig. 2b). This region prevents the exposure of GDP-fucose to the solvent and avoids the binding of a TSR. Similarly, HsPoFUT2 employs loop141–155 to selectively bind TSRs in contraposition to EGF repeat acceptor substrates (Valero-González et al., 2016; Li et al., 2017). Superimposition of both human enzymes complexed with GDP-fucose renders an r.m.s.d. on 167 equivalent Cα atoms of 2.62 Å, suggesting a higher fold similarity of the enzymes in the presence of the sugar donor in contrast to the free form.
For both enzymes, most of the residues involved in interaction with GDP-fucose are conserved. The essential residues Arg240HsPoFUT1/Arg294HsPoFUT2 interact with the β-phosphate of GDP-fucose through hydrogen-bonding and electrostatic interactions, which are conserved in other fucosyltransferases (Martinez-Duncker et al., 2003; Okajima et al., 2005; Lira-Navarrete et al., 2011; Chen et al., 2012; McMillan et al., 2017). The GDP moiety is tethered by additional interactions with Asn46/Asn57, His238/His292, Asp340/Asp371, Ser356/Ser387, Ser357/Thr388 and Phe358/Phe389 of HsPoFUT1 and HsPoFUT2, respectively (Fig. 3). GDP also interacts with the backbones of Phe44 and Gly45 in HsPoFUT1. Contrary to the high level of conservation between the interacting residues of HsPoFUT1 and HsPoFUT2 with the GDP moiety, the residues recognizing the fucose moiety are not conserved. In particular, the fucose moiety is stabilized by interactions with Arg43/Asp244 of HsPoFUT1 and Pro53/Gly55 of HsPoFUT2 (Fig. 3).
4. PoFUT1 and PoFUT2 deploy different strategies for protein-substrate recognition
The structures of both enzymes in complex with acceptor substrates highlight significant differences. Complexes between MmPoFUT1 and four different EGF repeats reveal that the binding mode of all repeats is preserved (Li et al., 2017). The EGF repeats locate near a hairpin formed by amino acids Val72–Ser91, which are highly conserved among different species (Lira-Navarrete et al., 2011). This particular hairpin moves to maintain contact with the EGF C5–C6 subdomain through hydrophobic interactions with residues His80 or Phe85 (Li et al., 2017). Other conserved interactions are made by MmPoFUT1 residues Phe266 and Met267 and an apolar residue located next to the fourth cysteine in the EGF repeats (Fig. 4a; Li et al., 2017). Finally, primary interactions between MmPoFUT1 and the different EGF repeats are formed by amino acids from the inner part of the MmPoFUT1 groove and the EGF consensus sequence. Within the consensus sequence, the hydrogen-bond interaction between the acceptor Ser/Thr and Asn51MmPoFUT1 is of the utmost importance for catalytic purposes (Li et al., 2017).
Looking at the CePoFUT2–GDP–HsTSR1 ternary complex, it is evident that both the interactions between the CePoFUT2–HsTSR1 and MmPoFUT1–EGF complexes and the arrangement of the TSR and EGF repeats differ (Valero-González et al., 2016; Li et al., 2017). The CePoFUT2–HsTSR1 complex is partly supported by direct interactions between two hydrophobic patches of CePoFUT2 and nonconserved residues of HsTSR1 (Fig. 4b). Three of the ten direct interactions between CePoFUT2 and HsTSR1 are conserved for other TSRs, suggesting that the complex is stabilized by a limited number of direct interactions. Within these three interactions, the hydrogen bond between the acceptor Ser or Thr and the catalytic base Glu52 is essential for catalysis (Valero-González et al., 2016).
A striking difference between the MmPoFUT1–EGF and CePoFUT2–HsTSR1 complexes is the large number of water molecules that are present in the interface of the latter. These water molecules mediate an important number of interactions through hydrogen bonds between the enzyme and HsTSR1 (Fig. 4b; Valero-González et al., 2016). The interactions provide an explanation at the molecular level of how PoFUT2 recognizes multiple dissimilar TSRs (Leonhard-Melief & Haltiwanger, 2010; Kakuda & Haltiwanger, 2014). Therefore, both PoFUT1 and PoFUT2 deploy different strategies to identify their acceptor-protein substrates. PoFUT2 recognizes TSRs by using a limited number of direct conserved interactions complemented by a large number of hydrogen-bond interactions mediated by water molecules (Valero-González et al., 2016). Meanwhile, PoFUT1 uses a water-filled cavity to accommodate the EGF loop C1–C2 (Li et al., 2017), although the main interactions rely on conserved direct hydrogen bonds between the enzyme and its protein substrate.
5. Catalytic mechanisms of PoFUT1 and PoFUT2
The ternary complexes also provided a better understanding of how the two enzymes achieve catalysis. These proteins are inverting GTs, implying that the acceptor Ser/Thr makes a nucleophilic attack on the nucleotide sugar anomeric C atom from the opposite side to the leaving nucleotide. As a result, this action inverts the anomeric stereochemistry (Lairson et al., 2008). In this mechanism, deprotonation of the acceptor hydroxyl group by a catalytic base, usually an aspartate or a glutamate, is required to increase the nucleophilic character of the acceptor residue and is a prior step to the attack of the acceptor on the anomeric C atom (Lairson et al., 2008; Breton et al., 2012). While an amino acid acting as a catalytic base is present in PoFUT2 (Glu54/Glu52 in human PoFUT2 and CePoFUT2, respectively), an equivalent residue is not found in PoFUT1. As expected, mutating Glu54 and Arg294 in HsPoFUT2 revealed that these two amino acids are essential for (Chen et al., 2012). Furthermore, the CePoFUT2–GDP–HsTSR1 complex, together with supports the role of a glutamate as the catalytic base. In this Glu52 was engaged in a hydrogen bond to the acceptor serine in the HsTSR1 repeat (Valero-González et al., 2016). Overall, these data support an SN2-like mechanism for PoFUT2 (Fig. 5b), which is the typical mechanism reported for most inverting glycosyltransferases (Lairson et al., 2008).
In contrast, an SN1-like mechanism was proposed for PoFUT1 (Fig. 5a) in which Asn43 of CePoFUT1 positions the incoming acceptor and Arg240 facilitates the cleavage of the glycosidic bond by interacting with the β-phosphate group (Lira-Navarrete et al., 2011). Michaelis complexes of MmPoFUT1 also support an SN1-like mechanism and confirm a similar arrangement as above. The equivalent residues in MmPoFUT1, Asn51 and Arg245, are engaged in hydrogen bonds to the acceptor residue and the β-phosphate group, respectively. Arg240CePoFUT1/Arg245MmPoFUT1 could also favour the reaction by stabilizing GDP. In addition, the acceptor hydroxyl group is close to a water molecule that is engaged in a hydrogen bond to the β-phosphate O atom. In concordance with an SN1-like mechanism, this water molecule could promote catalysis by providing a proton relay serving to shuttle the acceptor hydroxyl proton to the GDP β-phosphate O atom, which acts as the catalytic base (Li et al., 2017). This of PoFUT1 differs from that proposed for PoFUT2, and consists of prior cleavage of the glycosidic bond, followed by attack of the pre-activated acceptor hydroxyl group on the anomeric C atom.
6. Final remarks
PoFUT1 and PoFUT2 are glycosyltransferases that share great resemblances, including catalysis of the same type of PTM, architecture and the recognition of proteins with cysteine-rich repeats (Chen et al., 2012; Schneider et al., 2017). However, significant differences are present at the primary-structure and secondary-structure levels, accounting for the different arrangements of EGF repeats and TSRs in the binding site, the recognition mode of EGF repeats and TSRs, and the These differences explain why these enzymes serve specific substrates and are not capable of cross-recognizing their acceptor substrates. PoFUT2 has evolved to glycosylate two different groups of TSRs (Kakuda & Haltiwanger, 2014). In doing so, PoFUT2 employs a different strategy to recognize its TSRs by using a water-molecule network that mediates enzyme–protein substrate interactions (Valero-González et al., 2016). In addition, while the SN2-like mechanism of PoFUT2 is well accepted for inverting GTs, the atypical SN1-like mechanism proposed for PoFUT1 needs further validation by additional experiments.
We expect that these findings will be able to be leveraged for the development of inhibitors/modulators of PoFUT1/2 that would be useful for providing further insights into the role of this PTM in animal models and for diseases and pathologies associated with these enzymes.
Funding information
The work of the authors was supported by a postdoctoral EMBO fellowship ALTF 1553-2015 to EL-N co-funded by the European Commission (LTFCOFUND2013, GA-2013-609409) and Marie Curie Action, the ARAID Foundation, MICINN (CTQ2013-44367-C2-2-P and BFU2016-75633-P) and DGA (B89).
References
Allenspach, E. J., Maillard, I., Aster, J. C. & Pear, W. S. (2002). Cancer Biol. Ther. 1, 466–476. CrossRef Google Scholar
Benz, B. A., Nandadasa, S., Takeuchi, M., Grady, R. C., Takeuchi, H., LoPilato, R. K., Kakuda, S., Somerville, R. P. T., Apte, S. S., Haltiwanger, R. S. & Holdener, B. C. (2016). Dev. Biol. 416, 111–122. CrossRef Google Scholar
Bertozzi, C. R. & Rabuka, D. (2009). Essentials of Glycobiology, 2nd ed., edited by A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart & M. E. Etzler, pp. 23–36. New York: Cold Spring Harbor Laboratory Press. Google Scholar
Breton, C., Fournel-Gigleux, S. & Palcic, M. M. (2012). Curr. Opin. Struct. Biol. 22, 540–549. Web of Science CrossRef CAS PubMed Google Scholar
Chen, C.-I., Keusch, J. J., Klein, D., Hess, D., Hofsteenge, J. & Gut, H. (2012). EMBO J. 31, 3183–3197. CrossRef Google Scholar
D'Souza, B., Miyamoto, A. & Weinmaster, G. (2008). Oncogene, 27, 5148–5167. Google Scholar
Haltom, A. R. & Jafar-Nejad, H. (2015). Glycobiology, 25, 1027–1042. CrossRef Google Scholar
Hofsteenge, J., Huwiler, K. G., Macek, B., Hess, D., Lawler, J., Mosher, D. F. & Peter-Katalinic, J. (2001). J. Biol. Chem. 276, 6485–6498. CrossRef Google Scholar
Kakuda, S. & Haltiwanger, R. S. (2014). Handbook of Glycosyltransferases and Related Genes, 2nd ed., edited by N. Taniguchi, K. Honke, M. Fukuda, H. Narimatsu, Y. Yamaguchi & T. Angata, pp. 623–633. Tokyo: Springer. Google Scholar
Kelwick, R., Desanlis, I., Wheeler, G. N. & Edwards, D. R. (2015). Genome Biol. 16, 113. CrossRef Google Scholar
Kentzer, E. J., Buko, A., Menon, G. & Sarin, V. K. (1990). Biochem. Biophys. Res. Commun. 171, 401–406. CrossRef Google Scholar
Kroes, R. A., Dawson, G. & Moskal, J. R. (2007). J. Neurochem. 103, Suppl. 1, 14–24. Google Scholar
Lairson, L. L., Henrissat, B., Davies, G. J. & Withers, S. G. (2008). Annu. Rev. Biochem. 77, 521–555. Web of Science CrossRef PubMed CAS Google Scholar
Leonhard-Melief, C. & Haltiwanger, R. S. (2010). Methods Enzymol. 480, 401–416. Google Scholar
Li, Z., Han, K., Pak, J. E., Satkunarajah, M., Zhou, D. & Rini, J. M. (2017). Nature Chem. Biol. 13, 757–763. CrossRef Google Scholar
Lira-Navarrete, E., Valero-González, J., Villanueva, R., Martínez-Júlvez, M., Tejero, T., Merino, P., Panjikar, S. & Hurtado-Guerrero, R. (2011). PLoS One, 6, e25365. Web of Science PubMed Google Scholar
Loo, L. W. M., Tiirikainen, M., Cheng, I., Lum-Jones, A., Seifried, A., Church, J. M., Gryfe, R., Weisenberger, D. J., Lindor, N. M., Gallinger, S., Haile, R. W., Duggan, D. J., Thibodeau, S. N., Casey, G. & Le Marchand, L. (2013). Genes Chromosomes Cancer, 52, 450–466. CrossRef Google Scholar
Lopaticki, S., Yang, A. S. P., John, A., Scott, N. E., Lingford, J. P., O'Neill, M. T., Erickson, S. M., McKenzie, N. C., Jennison, C., Whitehead, L. W., Douglas, D. N., Kneteman, N. M., Goddard-Borger, E. D. & Boddey, J. A. (2017). Nature Commun. 8, 561. CrossRef Google Scholar
Luca, V. C., Jude, K. M., Pierce, N. W., Nachury, M. V., Fischer, S. & Garcia, K. C. (2015). Science, 347, 847–853. CrossRef Google Scholar
Luca, V. C., Kim, B. C., Ge, C., Kakuda, S., Wu, D., Roein-Peikar, M., Haltiwanger, R. S., Zhu, C., Ha, T. & Garcia, K. C. (2017). Science, 355, 1320–1324. CrossRef Google Scholar
Luo, Y., Koles, K., Vorndam, W., Haltiwanger, R. S. & Panin, V. M. (2006). J. Biol. Chem. 281, 9393–9399. CrossRef Google Scholar
Luo, Y., Nita-Lazar, A. & Haltiwanger, R. S. (2006). J. Biol. Chem. 281, 9385–9392. CrossRef Google Scholar
Martinez-Duncker, I., Mollicone, R., Candelier, J.-J., Breton, C. & Oriol, R. (2003). Glycobiology, 13, 1C–5C. Google Scholar
McMillan, B. J., Zimmerman, B., Egan, E. D., Lofgren, M., Xu, X., Hesser, A. & Blacklow, S. C. (2017). Glycobiology, 27, 777–786. CrossRef Google Scholar
Okajima, T., Xu, A., Lei, L. & Irvine, K. D. (2005). Science, 307, 1599–1603. CrossRef Google Scholar
Ricketts, L. M., Dlugosz, M., Luther, K. B., Haltiwanger, R. S. & Majerus, E. M. (2007). J. Biol. Chem. 282, 17014–17023. CrossRef Google Scholar
Savage, C. R. Jr, Hash, J. H. & Cohen, S. (1973). J. Biol. Chem. 248, 7669–7672. Google Scholar
Schneider, M., Al-Shareffi, E. & Haltiwanger, R. S. (2017). Glycobiology, 27, 601–618. CrossRef Google Scholar
Takeuchi, H. & Haltiwanger, R. S. (2014). Biochem. Biophys. Res. Commun. 453, 235–242. CrossRef Google Scholar
Valero-González, J., Leonhard-Melief, C., Lira-Navarrete, E., Jiménez-Osés, G., Hernández-Ruiz, C., Pallarés, M. C., Yruela, I., Vasudevan, D., Lostao, A., Corzana, F., Takeuchi, H., Haltiwanger, R. S. & Hurtado-Guerrero, R. (2016). Nature Chem. Biol. 12, 240–246. Google Scholar
Vasudevan, D., Takeuchi, H., Johar, S. S., Majerus, E. & Haltiwanger, R. S. (2015). Curr. Biol. 25, 286–295. CrossRef Google Scholar
Wang, L. W., Dlugosz, M., Somerville, R. P. T., Raed, M., Haltiwanger, R. S. & Apte, S. S. (2007). J. Biol. Chem. 282, 17024–17031. CrossRef Google Scholar
Wang. Y. & Spellman, M. W. (1998). J. Biol. Chem. 273, 8112–8118. CrossRef Google Scholar
Xu, A., Haines, N., Dlugosz, M., Rana, N. A., Takeuchi, H., Haltiwanger, R. S. & Irvine, K. D. (2007). J. Biol. Chem. 282, 35153–35162. CrossRef Google Scholar
Yokota, S., Ogawara, K., Kimura, R., Shimizu, F., Baba, T., Minakawa, Y., Higo, M., Kasamatsu, A., Endo-Sakamoto, Y., Shiiba, M., Tanzawa, H. & Uzawa, K. (2013). Int. J. Oncol. 43, 1864–1870. CrossRef Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.